Increased antibody response to microbial antigens in patients with Crohn's disease and their unaffected first-degree relatives

Digestive and Liver Disease

Volumn 45, Issue 11, 2013, Pages 894-898

  Michielan, Andrea ^a   Basso, Daniela ^b   Martinato, Matteo ^a   Pathak, Surajit ^a   Banerjee, Antara ^a   Oliva, Lydia ^a   Plebani, Mario ^b   Sturniolo, Giacomo Carlo ^a   D'Incà, Renata ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Antibodies; Crohn's disease; Relatives

Indexed keywords

ANTIBODY; CHITOBIOSIDE ANTIBODY; LAMINARIBIOSIDE ANTIBODY; MANNOBIOSIDE ANTIBODY; OUTER MEMBRANE PORIN C ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; FIRST DEGREE RELATIVE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SEROLOGY;

ANTIBODIES; CROHN'S DISEASE; RELATIVES;

ADOLESCENT; ADULT; ANTIBODIES; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIA; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAMILY; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTESTINE, SMALL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84885432174     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.01.017     Document Type: Article

References (43)

1. Sutton C.L., Kim J., Yamane A., et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000, 119:23-31.
2. Lodes M.J., Cong Y., Elson C.O., et al. Bacterial flagellin is a dominant antigen in Crohn disease. Journal of Clinical Investigation 2004, 113:1296-1306.
3. Landers C.J., Cohavy O., Misra R., et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002, 123:689-699.
4. Dotan I., Fishman S., Dgani Y., et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006, 131:366-378.
5. Probert C.S., Jayanthi V., Hughes A.O., et al. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and South Asians in Leicestershire. Gut 1993, 34:1547-1551.
6. Orholm M., Iselius L., Sørensen T.I., et al. Investigation of inheritance of chronic inflammatory bowel diseases by complex segregation analysis. British Medical Journal 1993, 306:20-24.
7. Orholm M., Fonager K., Sørensen H.T. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease. American Journal of Gastroenterology 1999, 94:3236-3238.
8. Russell R.K., Satsangi J. IBD: a family affair. Best Practice and Research. Clinical Gastroenterology 2004, 18:525-539.
9. Hollander D., Vadheim C.M., Brettholz E., et al. Increased intestinal permeability in patients with Crohn's disease and their healthy relatives. Annals of Internal Medicine 1986, 105:883-885.
10. May G.R., Sutherland L.R., Meddings J.B. Is small intestinal permeability really increased in relatives of patients with Crohn's disease?. Gastroenterology 1993, 104:1627-1632.
11. Munkholm P., Langholz E., Hollander D., et al. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first-degree relatives. Gut 1994, 35:1675-1676.
12. Peeters M., Geypens B., Claus D., et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997, 113:802-807.
13. D'Incà R., Annese V., di Leo V., et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Alimentary Pharmacology and Therapeutics 2006, 23:1455-1461.
14. Thjodleifsson B., Sigthorsson G., Cariglia N., et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives?. Gastroenterology 2003, 124:1728-1737.
15. Montalto M., Curigliano V., Santoro L., et al. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. American Journal of Gastroenterology 2007, 102:132-136.
16. Seibold F., Slametschka D., Gregor M., et al. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994, 107:532-536.
17. Shanahan F., Duerr R.H., Rotter J.I., et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992, 103:456-461.
18. Lee J.C., Lennard-Jones J.E., Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology 1995, 108:428-433.
19. Folwaczny C., Noehl N., Endres S.P., et al. Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1998, 33:523-528.
20. Sendid B., Quinton J.F., Charrier G., et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. American Journal of Gastroenterology 1998, 93:1306-1310.
21. Seibold F., Stich O., Hufnagl R., et al. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scandinavian Journal of Gastroenterology 2001, 36:196-201.
22. Mei L., Targan S.R., Landers C.J., et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 2006, 130:1078-1085.
23. Joossens M., Van Steen K., Branche J., et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Inflammatory Bowel Diseases 2010, 16:58-67.
24. Mow W.S., Vasiliauskas E.A., Lin Y.C., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004, 126:414-424.
25. Devlin S.M., Yang H., Ippoliti A., et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 2007, 132:576-586.
26. Vermeire S., Peeters M., Vlietinck R., et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflammatory Bowel Diseases 2001, 7:8-15.
27. Harrer M., Reinisch W., Dejaco C., et al. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease?. European Journal of Gastroenterology and Hepatology 2003, 15:1281-1285.
28. Lindberg E., Magnusson K.E., Tysk C., et al. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 1992, 33:909-913.
29. Konrad A., Rutten C., Flogerzi B., et al. Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease. Inflammatory Bowel Diseases 2004, 10:97-105.
30. Israeli E., Grotto I., Gilburd B., et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005, 54:1232-1236.
31. Papp M., Norman G.L., Altorjay I., et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic?. World Journal of Gastroenterology 2007, 13:2028-2036.
32. Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Digestive Diseases 2010, 28:418-423.
33. Ferrante M., Henckaerts L., Joossens M., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
34. Simondi D., Mengozzi G., Betteto S., et al. Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflammatory Bowel Diseases 2008, 14:645-651.
35. Peyrin-Biroulet L., Standaert-Vitse A., Branche J., et al. IBD serological panels: facts and perspectives. Inflammatory Bowel Diseases 2007, 13:1561-1566.
36. Rieder F., Schleder S., Wolf A., et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflammatory Bowel Diseases 2010, 16:263-274.
37. Seow C.H., Stempak J.M., Xu W., et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. American Journal of Gastroenterology 2009, 104:1426-1434.
38. Arnott I.D., Landers C.J., Nimmo E.J., et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. American Journal of Gastroenterology 2004, 99:2376-2384.
39. Halfvarson J., Standaert-Vitse A., Järnerot G., et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut 2005, 54:1237-1243.
40. Annese V., Lombardi G., Perri F., et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease - an IG-IBD study. American Journal of Gastroenterology 2005, 100:84-92.
41. Henckaerts L., Pierik M., Claes K.S., et al. Mutations in innate immune receptors modulate the serologic response to microbial antigens in patients with inflammatory bowel disease. American Journal of Gastroenterology 2006, A:T1974.
42. Papp M., Altorjay I., Norman G.L., et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflammatory Bowel Diseases 2007, 13:892-984.
43. Papp M., Altorjay I., Dotan N., et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. American Journal of Gastroenterology 2008, 103:665-681.